Biography:

Jes Paul has done Ph.D. in Neurology & Molecular Cell Biology, stem cells with 3 years’ post-doctoral training, Master’s degree with 7 years’ post-graduate training and Good Laboratory Practice (GLP).My publications include 15(Research gate, Pub med) Papers in international journals (Pub Med) and Presented 16 Abstracts in various international conferences and He is also a Editorial member of IRPH Journal since four years. Currently he is working as a Research Associate (Albany medical centre cardiovascular science).

Abstract:

Introduction: Parkinson’s disease (PD) is due to widespread degeneration in the central and peripheral nervous systems. The hallmark pathology remains in the dopaminergic striatal insufficiency and degeneration of dopaminergic neurons in the substantia nigra (SN).

 

Objectives: The present study analyzed the effect of serotonin (5-HT), dopamine and norepinephrine (NE) as treatment on rotenone induced hemi-Parkinson’s disease in rats and its role in the regulation of Dopamine receptor subtypes in the Corpus Straiatum (CS) of the experimental rats.

 

Methods: Unilateral stereotaxic single dose infusions of rotenone were administered to the substantia nigra of adult male Wistar rats. Neurotransmitters –serotonin (5-HT), dopamine and norepinephrine (NE) treatments were given to rotenone induced hemi-Parkinson’s rats. Dopamine receptor and its subtypes (D₁ and D₂) binding assay were done. Gene expression studies of Dopamine D₁ and D₂ were done using real-time PCR.

 

Results: Scatchard analysis of Dopamine and Dopamine D₂ receptor showed a significant increase (p<0.001) and Dopamine D₁ receptor showed a significant decrease (p<0.001) in the B_max in Corpus Striatum of the PD rats compared to control. These altered parameters were reversed to near control in the serotonin and norepinephrine treated Parkinson’s disease rats and no change was observed in Dopamine treated Parkinson’s disease rats. Real-time PCR results confirmed the receptor data.

 

Conclusion: Our results showed serotonin and norepinephrine functionally reversed in Dopamine receptors in rotenone induced hemi-Parkinson’s rat. This has clinical significance in the therapeutic management of Parkinson’s disease.

 

Biography:

Usman Shabbir, the CTO & cofounder of Trequant, is an Electrical Engineer and Electronics Expert by profession. He has interest in wearable gadgets, embedded systems and miniaturization of circuits. A passionate person about robotics and artificial intelligence has done different projects on automation of things and robots. He is the hardware geek for Trequant and currently working on hardware design and engineering. He has won fifteen national and international awards presenting his work at different stages.

Abstract:

Trequant is a bio-informatics wearable designed specifically for diagnosing and classifying tremor based movement disorders including Parkinson’s, essential tremor, dystonia and others. Tremors affects 221 million people worldwide including 15 million from USA and it is one of the most prevalent and incurable neurological disorder. The complete end-to-end solution we are providing includes a wearable device, an app on a mobile device, and our data analytics platform in the cloud. Currently Trequant device is being used by more than 50 patients and 2 hospitals. With the results and data recorded from our device, doctors are better able to understand their patient’s condition and with the help of our remote monitoring portal and they can see the effect of the prescribed medicine and can customize the type and dosage of the medicine according to every individual patient. Mobile app also helps patients in understanding what type of activities can make their tremors condition worse or good. At Trequant, we are all about having people that are afflicted with tremors live a more independent life and be more in control of their condition and actionable data is the answer to this.

Biography:

Steven J. Szydlowski has completed his Doctorate of Health Administration in 2007 from the Medical University of South Carolina and Master of Business Administration and Master of Health Administration from the University of Scranton. He is the director of the Master of Health Administration at the University of Scranton. He has published more than 40 papers in reputed journals, presented at over 100 national and international conferences, and has been serving as an editorial board member of repute. He research agena focuses on population health, integrative medicine, and global health. He has over fifteen years of health care administration

Abstract:

The use of holistic therapies in physical and behavioral medicine continues to expand nationally. Research supports the use of holistic therapies to improve health outcomes related to back pain, arthritis, and depression to name a few. This case study presentation demonstrates application of holistic therapies for individuals with physical ailments and movement disorders in an integrative medicine clininc in Northeast Pennsylvania. The holistic clinical team approach is discussed. The presenter provides the historical evolution of the clinic and desribes how the clinical protocols where developed. The presenter will also discuss how community-based engagement efforts where used to support individuals with movement disorders beyond physical medicine to include behavioral health. The findings suggest that holistic therapies do support quality of life and positive health outcomes when combined with traditional approaches to care for individual with movement therapies.  

Biography:

Dr. Senderovich is a physician at Baycrest Health Science System with practice focused on Palliative Care, Pain Medicine and Geriatrics. She is an  Assistant professor at the Department of Family and Community Medicine, and Division of Palliative Care at the University of Toronto who actively involved teaching medical students and residents. She has a broad international experience and a solid research background. Her research was accepted nationally and internationally. She is an author of multiple manuscripts focused on geriatrics, patient’s centered care, ethical and legal aspect of doctor patient relationship, palliative and end-of-life care. 

Abstract:

Introduction

Parkinson disease (PD) is an increasingly prevalent terminal illness in a globally aging population. Despite optimal medical management, prognosis remains poor – a fact seldom communicated to patients and/or their families.  Evidence suggests numerous benefits of palliative care consultation in advanced PD but to date, their services remain woefully underutilized.

 

Objectives

To identify specific challenges to accessing and implementing palliative care in patients with advanced PD, and to use this information to formulate recommendations for practice.

Methods

Literature review whereby recommendations for practice were formulated on the basis of primary quantitative/qualitative data and consensus expert opinion.

Results

Accessing palliative care services for patients with PD remains a challenge for numerous factors including prognostic uncertainty, misconceptions about what palliative care is, and difficulty recognizing when a patient is suitable for referral.  Strategies to improve access/delivery of palliative care to this population include education and proper discussion about prognosis/goals of care. A team-based approach is essential as we move towards a model where symptom palliation exists concurrently with active medical disease-modifying treatment.

Conclusion

Despite evidence that palliative care has a role in improving symptom control and overall quality of life in patients with end-stage PD, a multitude of challenges exist and this ultimately hinders access to palliative care services. Education to abolish pre-existing misconceptions about the role of palliative care and a movement towards a team-based approach focused on simultaneous palliative and traditional medical care will undoubtedly improve access to, and benefit from, palliative care services in this population.